Apsis Therapeutics, Ltd

Welcome to APSIS, APSIS Therapeutics, LTD. is an enterprise developing new chemical entities of therapeutic importance with its focus on novel nucleosides, nucleotide prodrugs, and modified CRISPR/Cas9 (lgRNA/Cas9). APSIS is dedicated to discovering, developing and commercializing cures for patients suffering from chronic viral infections, diseases caused by retrovirus (HIV) and DNA virus (HSV, HBV), and certain cancers. APSIS Therapeutics, LTD. welcomes partnering and licensing opportunities. Apsis Biochem is one source of novel modified nucleosides, nucleotides, and phosphoramidites (including triphosphates and phosphoramidites of therapeutic nucleos(t)ides, isotope-labeled nucleotides, fluorescent nucleotides, and nucleotide conjugates) for biological research and medical and biotechnological applications in genomics, nucleos(t)ide chemotherapeutic discovery, and oligonucleotide therapeutic discovery. Apsis develops better or alternative chemical processes for nucleoside and nucleotide APIs (active pharmaceutical ingredient), especially in purine nucleosides (PurSelect). Licensing opportunities are available.